Biokin Pharmaceutical 百利天恒
5 significant filings since 30 May 2026: 4 on buyback and 1 on major contract or bid won. The latest, on 22 Sep 2026: 四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告.
自 30 May 2026 起有 5 份重大公告：buyback 4 份、major contract or bid won 1 份。最新一份（22 Sep 2026）：四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | -2.72 | -2.43 |
| 7 days ago | -2.72 | -2.43 |
| 30 days ago | -2.72 | -2.43 |
| 60 days ago | -2.72 | -2.43 |
| 90 days ago | -2.72 | -2.43 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from -2.66 in May 2025 to -2.72 in Sep 2026 (-2.3%). 一致预期从 May 2025 的 -2.66 变为 Sep 2026 的 -2.72 (-2.3%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 1 = 1 | ▲ 0 ▼ 1 = 1 |
| Last 90 days | ▲ 0 ▼ 1 = 1 | ▲ 0 ▼ 1 = 1 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0.